Tools such as this can assist clinicans as they make decisions about which populations will benefit most from acute coronary interventions, more advanced antitrombin therapies or the use of newer antiplatelet agents. This study provides a practical and fairly easy to use method by which practitioners can risk stratify patients presenting with acute coronary syndromes. American Heart Journal 2002, 143 (6): 966-70 The TIMI Risk Score (NSTEMI) calculator is created by QxMD. The greatest benefit of low molecular weight heparin compared to unfractionated heparin occurred in patients with multiple risk variables, particularly those with four or more of the seven high-risk markers. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. unfractionated heparin in patients at various risk levels. The analysis also compared the relative benefit of low molecular weight heparin (enoxaparin) vs. The rate of the composite endpoint varied from as low as 4.7% in patients with no or one marker to a level of 40.9% in those with six or seven of the markers noted. Patients with no or one variable had a mortality rate of 1.2%, those with four variables had 2.5% and those with six or seven markers had a mortality rate of 6.5%. By aggregating patients with 0 to as many as 7 markers, a corresponding stepwise increase in the overall risk of mortality, myocardial infarction and urgent revascularization was observed. The seven independent predictor variables of the combined endpoints included age > 65 years, three or more risk factors for coronary heart disease, known prior coronary stenosis of at least 50%, ST-segment elevation or depression on presenting electrocardiography, two or more anginal episodes in the preceding 24 hours, aspirin use within a week of presentation and elevated serum markers of myocardial injury.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |